A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

Inclusion criteria:

Tissue from an archived or fresh tumor sample
A peripheral blood buffy coat sample is required for CLL/SLL.
Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic lymphocytic leukemia (CLL)/SLL or diffuse large B cell lymphoma
Patient > or = 18 years old
Eastern Cooperative Oncology Group (ECOG) performance status < or = 2. Patients with DLBCL will have ECOG < or = 1
Adequate white blood cells and hemoglobin
Good kidney and liver function
Fasting glucose < 160 mg/dL
No other malignancy
Use of adequate birth control

Exclusion criteria:

Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment
Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of the drug or its active metabolites (whichever is longer) of study enrollment
Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with temsirolimus is permitted in patients enrolled from countries where it is licensed for this indication.
Radiation therapy within 2 weeks of enrollment
Autologous stem cell transplantation within 16 weeks of enrollment
Prior allogeneic transplantation except for patients with R/R DLBCL who meet inclusion criteria
Central nervous system (CNS) or leptomeningeal involvement. Patients with DLBCL may have active CNS or leptomeningeal involvement.
Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV) serology
Primary CNS lymphoma
Primary mediastinal B-lymphoma

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.